aTyr Pharma (ATYR) Stock Surges 5% After FDA Protocol Agreement for Sarcoidosis Trial

Key Highlights

• aTyr Pharma secured FDA protocol agreement for its Phase 3 clinical trial evaluating efzofitimod in patients with pulmonary sarcoidosis.
• Study-related activities are scheduled to commence in Q4 2026.
• ATYR shares increased 5% after the regulatory update.
• The clinical trial will recruit approximately 372 participants over a 54-week duration.
• Trial design draws on positive subgroup findings from the previous EFZO-FIT Phase 3 study.

aTyr Pharma (ATYR) shares advanced 5% during Wednesday’s trading session following the biotechnology company’s disclosure that it achieved regulatory alignment with the U.S. Food and Drug Administration. The agreement covers the protocol design for an upcoming Phase 3 clinical trial evaluating efzofitimod as a treatment for chronic pulmonary sarcoidosis.

aTyr Pharma, Inc., ATYR

The California-based biopharmaceutical firm disclosed its intention to initiate trial-related operations during the final quarter of 2026. Concurrently, the company will concentrate efforts on submitting regulatory applications to authorities in the United States and European markets.

Pulmonary sarcoidosis represents a category of interstitial lung disease that leaves patients struggling with restricted therapeutic alternatives, particularly individuals requiring extended treatment regimens.

Trial Design and Structure

The planned Phase 3 investigation will adopt a global, randomized, double-blind, placebo-controlled format. Scientists structured the protocol to assess both therapeutic effectiveness and safety profiles of efzofitimod in individuals experiencing moderate to severe disease manifestations.

The clinical study spans 54 weeks in duration. Enrolled subjects will be randomly assigned to one of two equal cohorts, administering either 5.0 mg/kg of efzofitimod or matching placebo through intravenous infusion every three weeks across 17 total doses.

aTyr anticipates recruiting approximately 372 study participants. Qualified candidates must maintain a stable regimen of low-dose oral corticosteroids or background immunosuppressive medication, with these baseline therapies remaining unchanged throughout the investigation period.

Researchers designated forced vital capacity change from baseline to week 48 as the primary efficacy measure. An important secondary assessment will monitor modifications in King’s Sarcoidosis Questionnaire-Lung scoring during the identical timeframe.

Foundation in Previous Clinical Results

The protocol design stems from rigorous scientific groundwork. It relies heavily on subgroup analysis data extracted from the preceding EFZO-FIT Phase 3 investigation.

That retrospective analysis examined patients presenting with restrictive lung disease characteristics, specifically those demonstrating forced vital capacity readings at 80% or below predicted values alongside normal FEV1/FVC ratios. These individuals exhibited significant lung function improvements when administered the 5.0 mg/kg dosage relative to placebo recipients.

Beyond lung function metrics, participants experienced positive shifts across various patient-reported outcome measures, including KSQ-Lung assessments. aTyr shared these research outcomes during the World Association of Sarcoidosis and Other Granulomatous Disorders 2026 Congress presentation.

Chief Executive Officer Sanjay Shukla confirmed the company obtained FDA guidance early in the week, characterizing the regulatory alignment as a significant achievement. He emphasized the substantial unmet medical need facing chronic sarcoidosis patients as evidence of the drug candidate’s potential therapeutic value.

Efzofitimod functions as a biologic immunomodulatory agent. Its mechanism targets activated myeloid cell populations via neuropilin-2 receptor engagement, designed to resolve inflammatory processes while avoiding broad-spectrum immune system suppression.

The therapeutic candidate is simultaneously undergoing evaluation in a separate Phase 2 investigation for systemic sclerosis-associated interstitial lung disease. This parallel study, designated EFZO-CONNECT, continues progressing alongside the sarcoidosis development program.

aTyr acknowledged that advancing the Phase 3 sarcoidosis trial forward will necessitate securing additional financial resources. The organization indicated it may explore various funding mechanisms including equity or debt financing instruments, grant opportunities, strategic collaborations or licensing arrangements.

The company’s statement did not specify particular funding timelines or capital requirement amounts.